CDKN2A and acute lymphoblastic leukemia: We identified a loss of several critical oncogenic drivers of both B- and T-ALL following knockdown of METTL3, METTL13 and METTL14, including TAL1, LEF1 and CREBBP, as well as an upregulation of tumor suppressor CDKN2A.